Schlich Ltd +44(0) 1903 717001 info@schlich.co.uk
  • EN
  • 中文
  • 한국어
  • 日本語
  • Client Portal
Schlich Ltd
  • Our Firm
  • IP Services
    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy
  • Patent Specialities
    • Life Sciences & Biotech
    • Chemical & Pharmaceutical
    • Mechanical, Engineering and Physics
    • Software, Electronics and Communications
  • Insights
  • Inventors’ Zone
  • Contact
Select Page
The Federal Circuit clarifies conflicts arising between Patent Term Adjustment and Obviousness-type Double Patenting

The Federal Circuit clarifies conflicts arising between Patent Term Adjustment and Obviousness-type Double Patenting

by David Eyre | Sep 16, 2024 | US & International

Background  For valuable inventions it is relatively typical for a US patent to be expanded into a family of patent rights. Naturally, the value of patents is further enhanced by extra patent term.  Patents with expiry dates beyond the normal 20 year period can be...
First Revocation Decision of the UPC Confirms the European Approach to Antibody Inventions

First Revocation Decision of the UPC Confirms the European Approach to Antibody Inventions

by Juliette Boynton | Aug 28, 2024 | UPC

The matter started when Amgen sued various Sanofi companies and Regeneron for patent infringement of their EP3666797 patent.  The patent claims an antibody that binds to the catalytic domain of a PCSK9 protein and its use in treating or preventing...
Food for fork: stretchy cheese and contradictory post-filed evidence

Food for fork: stretchy cheese and contradictory post-filed evidence

by Sean Hughes | Jul 11, 2024 | EPO

Vegan Cheese Product Claim T 0629/22 concerned European patent no. 3422865 (subject-matter: vegan cheese and preparation thereof). The product claim was distinguished from the prior art according to the type and amount of starch used in the vegan cheese. However, the...
Therapeutic Effect – a Higher Bar for Novelty than for Sufficiency at the EPO

Therapeutic Effect – a Higher Bar for Novelty than for Sufficiency at the EPO

by David Eyre | Jul 8, 2024 | EPO

These provisions for “second medical use” also rely on the claims for use in a method of treatment being interpreted to include the physiological or technical effect of the treatment as being a functional feature of the claim.   However, the interpretation...
New Hope for Antibody Claims in the US

New Hope for Antibody Claims in the US

by Juliette Boynton | Jul 2, 2024 | US & International

However, in a significant development we now report, means-plus-function language for a claim to an antibody complied with both of the USPTO requirements for written description and for the claim not to be indefinite. Where functional language alone is used in US...
« Older Entries
Next Entries »

Search

Recent Posts

  • Squeezed Out! AstraZeneca overturns Wyeth’s $107.5M Infringement Award
  • UPC Court of Appeal Confirms Lock-in Danger
  • When “Monotherapy” Means Monotherapy: A Cautionary Tale on Claim Interpretation and Added Matter at the EPO
  • Has the EPO TBA Demolished the Essentiality Test?
  • A Clear Way Forward for Description Amendments: Decision Issued in G 1/25

Recent Comments

    CIPA
    IPReg
    CITMA
    • Instagram

    Services

    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy

    About

    • Our Firm
    • Careers
    • Our People
    • Policies

    Contact

    • Contact
    • Inventors Zone
    © 2026 Schlich, All rights reserved | Built by Molokini
    European Patent and Trade Mark Attorneys. Schlich Ltd is a UK limited company, registration no. 05238489, address: 9 St Catherine's Road, Littlehampton, West Sussex, BN17 5HS.